Tips to avoid patent pitfalls as market for RNAi-derived therapeutics grows

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Tips to avoid patent pitfalls as market for RNAi-derived therapeutics grows

Sponsored by

Logo 22.07.22.png
Patented Patent Copyright Law Business technology concept.

Anne Marie Clark, senior patent searcher at CAS, looks at ways to protect and commercialise the promise of RNAi

The value and complexity of the patent landscape around RNA interference (RNAi) is increasing, creating special challenges for patent searches to protect IP and maximise its value.

RNAi is claimed in a variety of ways within patents. Standard terminology is not always used, and chemical modifications can be described a variety of ways. These inconsistencies mean that there is no single search strategy that can be used to efficiently and comprehensively retrieve this information from different data sources.

Read an in-depth discussion of relevant challenges and search techniques for RNAi in this resource from CAS

Click here to access CAS’s content hub on Managing IP

more from across site and SHARED ros bottom lb

More from across our site

A decision on a licensing rate payable by Warner Bros and Paramount, and a survey outlining UK businesses’ lack of IP preparation ahead of launching abroad, were among other major talking points
A fresh wave of deals highlights why investors favour IP firms and why independent outfits may soon have to rethink their strategy
King & Spalding has now hired 15 partners from Winston Taylor and legacy firm Winston & Strawn in offices spanning Texas, San Francisco, and Chicago
Firm says its work with a biotech client could signal a sea change in how - and when - law firms enter the drug development process
Evan Lazerowitz, attorney in Robinson + Cole’s bankruptcy and reorganisation group, offers key takeaways for IP interested parties in bankruptcy and insolvency proceedings
While the UK sees heavy IP rankings movement, Germany’s new tiered UPC table signals a shift from early adoption to market maturity
In an exclusive interview, Bernard Ledeboer reveals how a Consolid-backed group of firms wants to expand across Europe, invest in AI and centralise operations to compete at the top tier
Not all private equity firms are the same, so leaders at four externally backed IP firms came together to discuss the frameworks they followed and how they ensured a cultural fit
Top-tier German and Spanish firms are among the advisers on a Europe-wide copyright and licensing tussle concerning the design of the track circuit in Madrid
Partners Alex Wilson and Andreas Kramer say bigger law firm rivals don’t necessarily gain by having a wider jurisdictional reach
Gift this article